The relationship of endogenous sex hormones (SH) with vascular endothelial function and with cardiovascular disease (CVD) is incompletely understood. We examined the associations between SH and endothelial function measured by brachial artery flow-mediated dilation (FMD).
Materials and Methods:
We included 1368 postmenopausal women and 1707 men, free of clinical CVD, participating in MESA Visit 1 (2000–2002). Serum SH [total testosterone, SH binding globulin (SHBG), dehydroepiandrosterone (DHEA), estradiol] were measured; free testosterone was calculated. The percent FMD difference (%FMD) was measured by high-resolution ultrasound. Using multivariable-adjusted linear regression, we tested the cross-sectional associations of SH (log transformed, compared per one SD increment) with %FMD.
Results:
The mean age of women and men were 64.2 and 61.4 years, respectively. Among women, after adjusting for demographics, CVD risk factors, and hormone therapy, higher SHBG was associated with greater %FMD [β = 0.215% (95% CI 0.026–0.405)], whereas higher free testosterone was associated with a smaller %FMD [−0.209% (−0.402, −0.017)]. Estradiol and DHEA were not associated with %FMD in women after multivariable adjustment. There was an age interaction, with higher free testosterone and lower SHBG associated with worse FMD in women <65 years of age, but not in those ≥65 years (p = 0.04). We did not see similar associations in men.
Conclusions:
A more androgenic SH profile of higher free testosterone and lower SHBG was associated with worse %FMD in postmenopausal women. Changes in SH with aging and menopause may result in vascular changes in women. Further studies are needed to assess longitudinal changes in SH levels and their association with vascular function.
Get full access to this article
View all access options for this article.
References
1.
BenjaminEJ, BlahaMJ, ChiuveSE, et al.Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation, 2017; 135:e146–e603.
2.
LernerDJ, KannelWB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J, 1986; 111:383–390.
3.
MukaT, Oliver-WilliamsC, KunutsorS, et al.Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. JAMA Cardiol, 2016; 1:767–776.
4.
MukaT, VargasKG, JaspersL, et al.Estrogen receptor beta actions in the female cardiovascular system: A systematic review of animal and human studies. Maturitas, 2016; 86:28–43.
5.
RossouwJE, AndersonGL, PrenticeRL, et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288:321–333.
6.
HulleyS, GradyD, BushT, et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998; 280:605–613.
7.
TraishAM, GaloosianA. Androgens modulate endothelial function and endothelial progenitor cells in erectile physiology. Korean J Urol, 2013; 54:721–731.
8.
IantornoM, WeissRG. Using advanced noninvasive imaging techniques to probe the links between regional coronary artery endothelial dysfunction and atherosclerosis. Trends Cardiovasc Med, 2014; 24:149–156.
RossR. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature, 1993; 362:801–809.
11.
von MeringGO, ArantCB, WesselTR, et al.Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: Results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation, 2004; 109:722–725.
12.
HayashiT, YamadaK, EsakiT, et al.Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun, 1995; 214:847–855.
KeaneyJFJr., ShwaeryGT, XuA, et al.17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation, 1994; 89:2251–2259.
15.
BellDR, RensbergerHJ, KoritnikDR, KoshyA. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries. Am J Physiol, 1995; 268:H377–383.
16.
FlorianM, FreimanA, MagderS. Treatment with 17-beta-estradiol reduces superoxide production in aorta of ovariectomized rats. Steroids, 2004; 69:779–787.
17.
MuehlfelderM, Arias-LozaPA, FritzemeierKH, PelzerT. Both estrogen receptor subtypes, ERalpha and ERbeta, prevent aldosterone-induced oxidative stress in VSMC via increased NADPH bioavailability. Biochem Biophys Res Commun, 2012; 423:850–856.
18.
Arias-LozaPA, MuehlfelderM, PelzerT. Estrogen and estrogen receptors in cardiovascular oxidative stress. Pflugers Arch, 2013; 465:739–746.
19.
Rocha de SousaPT, Breithaupt-FaloppaAC, de Jesus CorreiaC, et al.17beta-Estradiol prevents mesenteric injury induced by occlusion of the proximal descending aorta in male rats. J Vasc Surg, 2018; 67:597–606.
20.
HurtadoR, CelaniM, GeberS. Effect of short-term estrogen therapy on endothelial function: A double-blinded, randomized, controlled trial. Climacteric, 2016; 19:448–451.
21.
El KhoudarySR, BrooksMM, ThurstonRC, MatthewsKA. Lipoprotein subclasses and endogenous sex hormones in women at midlife. J Lipid Res, 2014; 55:1498–1504.
22.
JaspersL, DhanaK, MukaT, et al.Sex Steroids, Sex hormone-binding globulin and cardiovascular health in men and postmenopausal women: The Rotterdam Study. J Clin Endocrinol Metab, 2016; 101:2844–2852.
23.
TziomalosK, AthyrosVG, KaragiannisA, MikhailidisDP. Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis, 2010; 20:140–146.
24.
KimJA, MontagnaniM, ChandrasekranS, QuonMJ. Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin, 2012; 8:589–607.
25.
RechCM, ClapauchR, de SouzaM, BouskelaE. Low testosterone levels are associated with endothelial dysfunction in oophorectomized early postmenopausal women. Eur J Endocrinol, 2016; 174:297–306.
26.
ZhaoD, GuallarE, OuyangP, et al.Endogenous sex hormones and incident cardiovascular disease in post-menopausal women. J Am Coll Cardiol, 2018; 71:2555–2566.
27.
RosanoGM, SpoletiniI, VitaleC. Cardiovascular disease in women, is it different to men? The role of sex hormones. Climacteric, 2017; 20:125–128.
28.
AkishitaM, HashimotoM, OhikeY, et al.Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res, 2007; 30:1029–1034.
29.
BildDE, BluemkeDA, BurkeGL, et al.Multi-Ethnic Study of Atherosclerosis: Objectives and design. Am J Epidemiol, 2002; 156:871–881.
30.
YeboahJ, CrouseJR, BluemkeDA, et al.Endothelial dysfunction is associated with left ventricular mass (assessed using MRI) in an adult population (MESA). J Hum Hypertens, 2011; 25:25–31.
31.
YingW, ZhaoD, OuyangP, et al.Sex Hormones and Change in N-Terminal Pro-B-Type Natriuretic Peptide Levels: The Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab, 2018; 103:4304–4314.
32.
SubramanyaV, ZhaoD, OuyangP, et al.Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas, 2018; 108:37–44.
33.
SubramanyaV, Ambale-VenkateshB, OhyamaY, et al.Relation of Sex Hormone Levels with Prevalent and 10-year Change in Aortic Distensibility Assessed by MRI: The Multi-Ethnic Study of Atherosclerosis. Am J Hypertens, 2018; 31:774–783.
34.
SodergardR, BackstromT, ShanbhagV, CarstensenH. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem, 1982; 16:801–810.
35.
WangL, SzkloM, FolsomAR, CookNR, GapsturSM, OuyangP. Endogenous sex hormones, blood pressure change, and risk of hypertension in postmenopausal women: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2012; 224:228–234.
36.
YeboahJ, FolsomAR, BurkeGL, et al.Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: The multi-ethnic study of atherosclerosis. Circulation, 2009; 120:502–509.
37.
YeboahJ, CrouseJR, HsuFC, BurkeGL, HerringtonDM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation, 2007; 115:2390–2397.
38.
LeveyAS, StevensLA, SchmidCH, et al.A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009; 150:604–612.
39.
SkaugEA, AspenesST, OldervollL, et al.Age and gender differences of endothelial function in 4739 healthy adults: The HUNT3 Fitness Study. Eur J Prev Cardiol, 2013; 20:531–540.
40.
LundbergJO, GladwinMT, WeitzbergE. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov, 2015; 14:623–641.
41.
Bairey MerzCN, PepineCJ, WalshMN, FlegJL. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Circulation, 2017; 135:1075–1092.
42.
VirmaniR, KolodgieFD, BurkeAP, FarbA, SchwartzSM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 2000; 20:1262–1275.
RosanoGM, CollinsP, GerbaraO, et al.Effect of estradiol 17beta upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients. Int J Cardiol, 2006; 107:254–259.
CollinsP, RosanoGM, SarrelPM, et al.17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation, 1995; 92:24–30.
NoferJR. Estrogens and atherosclerosis: Insights from animal models and cell systems. J Mol Endocrinol, 2012; 48:R13–29.
51.
ReisSE, GlothST, BlumenthalRS, et al.Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation, 1994; 89:52–60.
52.
HodisHN, MackWJ, HendersonVW, et al.Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med, 2016; 374:1221–1231.
53.
HerringtonDM, ReboussinDM, BrosnihanKB, et al.Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med, 2000; 343:522–529.
54.
WatersDD, AldermanEL, HsiaJ, et al.Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA, 2002; 288:2432–2440.
55.
ClarkeSC, KelleherJ, Lloyd-JonesH, SlackM, SchofielPM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT atherosclerosis study. BJOG, 2002; 109:1056–1062.
56.
RossouwJE, PrenticeRL, MansonJE, et al.Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 2007; 297:1465–1477.
57.
NewG, TimminsKL, DuffySJ, et al.Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol, 1997; 29:1437–1444.
58.
McCrohonJA, WaltersWA, RobinsonJT, et al.Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol, 1997; 29:1432–1436.
59.
WebbCM, McNeillJG, HaywardCS, de ZeiglerD, CollinsP. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation, 1999; 100:1690–1696.
60.
HermanSM, RobinsonJT, McCredieRJ, AdamsMR, BoyerMJ, CelermajerDS. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol, 1997; 17:2004–2009.
61.
SubramanyaV, ZhaoD, OuyangP, et al.Association of endogenous sex hormone levels with coronary artery calcium progression among post-menopausal women in the Multi-Ethnic Study of Atherosclerosis (MESA). J Cardiovasc Comput Tomogr, 2019; 13:41–47.
62.
KhazaiB, GoldenSH, ColangeloLA, et al.Association of endogenous testosterone with subclinical atherosclerosis in men: The multi-ethnic study of atherosclerosis. Clin Endocrinol (Oxf), 2016; 84:700–707.
63.
HuberDA, BazilioD, LorenzonF, et al.Cardiovascular autonomic responses in the VCD rat model of menopause: Effects of short- and long-term ovarian failure. Reprod Sci, 2018; 25:1093–1105.
64.
OuyangP, MichosED, KarasRH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol, 2006; 47:1741–1753.
65.
AtkinsonG, BatterhamAM. The percentage flow-mediated dilation index: A large-sample investigation of its appropriateness, potential for bias and causal nexus in vascular medicine. Vasc Med, 2013; 18:354–365.
66.
KershawKN, Lane-CordovaAD, CarnethonMR, TindleHA, LiuK. Chronic Stress and Endothelial Dysfunction: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens, 2017; 30:75–80.
67.
LakattaEG, WangM, NajjarSS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am, 2009; 93:583–604.
68.
DibbleCT, ShimboD, BarrRG, et al.Brachial artery diameter and the right ventricle: The Multi-Ethnic Study of Atherosclerosis-right ventricle study. Chest, 2012; 142:1399–1405.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
